Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May 24;13(11):1836.
doi: 10.3390/diagnostics13111836.

Minimally Invasive Treatment Options for Hepatic Uveal Melanoma Metastases

Affiliations
Review

Minimally Invasive Treatment Options for Hepatic Uveal Melanoma Metastases

Abin Sajan et al. Diagnostics (Basel). .

Abstract

Uveal melanoma is one of the most common primary intraocular malignancies that accounts for about 85% of all ocular melanomas. The pathophysiology of uveal melanoma is distinct from cutaneous melanoma and has separate tumor profiles. The management of uveal melanoma is largely dependent on the presence of metastases, which confers a poor prognosis with a one-year survival reaching only 15%. Although a better understanding of tumor biology has led to the development of novel pharmacologic agents, there is increasing demand for minimally invasive management of hepatic uveal melanoma metastases. Multiple studies have already summarized the systemic therapeutic options available for metastatic uveal melanoma. This review covers the current research for the most prevalent locoregional treatment options for metastatic uveal melanoma including percutaneous hepatic perfusion, immunoembolization, chemoembolization, thermal ablation, and radioembolization.

Keywords: interventional radiology; liver metastases; locoregional therapy; uveal melanoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Illustration of the PHP system. With permission from Delcath Systems, Inc.

References

    1. Carvajal R.D., Schwartz G., Tezel T., Marr B., Francis J.H., Nathan P.D. Metastatic disease from uveal melanoma: Treatment options and future prospects. Br. J. Ophthalmol. 2017;101:38–44. doi: 10.1136/bjophthalmol-2016-309034. - DOI - PMC - PubMed
    1. Beasley A.B., Preen D.B., McLenachan S., Gray E.S., Chen F.K. Incidence and mortality of uveal melanoma in Australia (1982–2014) Br. J. Ophthalmol. 2023;107:406–411. doi: 10.1136/bjophthalmol-2021-319700. - DOI - PMC - PubMed
    1. Strashilov S., Yordanov A. Aetiology and Pathogenesis of Cutaneous Melanoma: Current Concepts and Advances. Int. J. Mol. Sci. 2021;22:6395. doi: 10.3390/ijms22126395. - DOI - PMC - PubMed
    1. Wei A.Z., Uriel M., Porcu A., Manos M.P., Mercurio A.C., Caplan M.M., Hulse L., Seedor R., Holovatska M., Francis J., et al. Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastases. Front. Oncol. 2022;12:961517. doi: 10.3389/fonc.2022.961517. - DOI - PMC - PubMed
    1. Stålhammar G., Herrspiegel C. Long-term relative survival in uveal melanoma: A systematic review and meta-analysis. Commun. Med. 2022;2:18. doi: 10.1038/s43856-022-00082-y. - DOI - PMC - PubMed

LinkOut - more resources